U S Physical Therapy Inc: Form 10-Q for the period ended Mar 31, 2014
Filed with the SEC on May 9, 2014 and accepted by EDGAR at May 9, 2014, 15:24 ET.
Management's discussion and analysis
As filed, 19,399 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
EXECUTIVE SUMMARY
Our Business
We operate outpatient physical therapy clinics that provide preventive and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. As of March 31, 2014, we operated 472 clinics in 43 states.
We also manage physical therapy facilities for third parties, primarily physicians, with 17 third-party facilities under management as of March 31, 2014.
On September 30, 2013, we sold the remainder of our physician services business. The results of operations and the loss on the sale of the physician services business have been reclassified to discontinued operations for all periods presented.
The following discussion refers to continuing operations unless otherwise noted.
During 2013, we acquired the following physical therapy clinic groups:
| Acquisition | Date | % Interest Acquired | Number of Clinics |
|---|---|---|---|
| February 2013 Acquisition | February 28 | 72% | 9 |
| April 2013 Acquisition | April 30 | 50% | 5 |
| May 2013 Acquisition | May 24 | 80% | 5 |
| December 9, 2013 Acquisition | December 9 | 60% | 12 |
| December 13, 2013 Acquisition | December 13 | 90% | 11 |
In addition to the above clinic group acquisitions, in 2013, the Company, through three of its subsidiaries, acquired three physical therapy clinic practices in separate transactions.
During the three months ended March 31, 2014, we did not acquire any clinic groups, however, we did acquire two individual clinic practices in separate transactions. One of the acquired clinics will operate as a satellite of one of our partnerships and the other will be consolidated into an existing clinic.
The results of operations of the acquired clinics have been included in our consolidated financial statements since the date of their acquisition.
Selected Operating and Financial Data
The following table presents selected operating and financial data that we believe are key indicators of our operating performance.
| For the Three Months Ended March 31, 2014 | 2013 | |
|---|---|---|
| Number of clinics, at the end of period | 472 | 441 |
| Working days | 63 | 63 |
| Average visits per day per clinic | 21.6 | 21.1 |
| Total patient visits | 643,869 | 577,573 |
| Net patient revenue per visit | $106.23 | $106.36 |
19
RESULTS OF OPERATIONS
Three Months Ended March 31, 2014 Compared to the Three Months Ended March 31, 2013
- Net revenues increased to $69.8 million for the three months ended March 31, 2014 (“2014 First Quarter”) from $62.8 million for the three months ended March 31, 2013 (“2013 First Quarter”) primarily due to an increase in visits of 66,000 from 578,000 for the 2013 First Quarter to 644,000 for the 2014 First Quarter offset by a small decrease in the average net patient revenue per visit for the 2014 First Quarter to $106.23 from $106.36 in the 2013 First Quarter.
- Net income attributable to our common shareholders for the 2014 First Quarter was $4.2 million versus $3.9 million for the 2013 First Quarter. Net income was $0.35 per diluted share for the 2014 period and $0.32 for the 2013 period. Total diluted shares were 12.1 million for the 2014 First Quarter and 12.0 million for the 2013 First Quarter.
Net Patient Revenues
- Net patient revenues increased to $68.4 million for the 2014 First Quarter from $61.4 million for the 2013 First Quarter, an increase of $7.0 million, or 11.3%, due to an increase in visits of 65,000 from clinics opened and acquired between April 1, 2013 and March 31, 2014 (“New Clinics”) and a slight increase in visits of 1,000 from clinics opened or acquired prior to April 1, 2013 (“Mature Clinics”). The increase was partially offset by a slight decrease in the net patient revenue per visit of $0.13.
- Net patient revenues related to New Clinics amounted to $7.9 million for the 2014 First Quarter and net patient revenues for Mature Clinics decreased by $0.9 million for the 2014 First Quarter as compared to the 2013 First Quarter.
Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates.
Other Revenues
Other revenues increased $46,000 in the 2014 First Quarter to $1,370,000 from $1,324,000 in the 2013 First Quarter.
Clinic Operating Costs
Clinic operating costs as a percentage of net revenues were $53.1 million, or 76.1% of net revenues, for the 2014 First Quarter and $47.9 million, or 76.3% of net revenues, for the 2013 First Quarter. The increase was primarily attributable to $6.6 million in operating costs of New Clinics offset by a decrease in operating costs of $1.4 million for Mature Clinics. Each component of clinic operating costs is discussed below:
Clinic Operating Costs—Salaries and Related Costs
Salaries and related costs increased to $37.9 million for the 2014 First Quarter from $34.1 million for the 2013 First Quarter, an increase of $3.8 million, or 11.4%. Salaries and related costs for New Clinics amounted to $4.4 million for the 2014 First Quarter. Salaries and related costs for Mature Clinics decreased by $0.6 million for the 2014 First Quarter as compared to the 2013 First Quarter. Salaries and related costs as a percentage of net revenues were 54.4% for the 2014 First Quarter and 54.3% for the 2013 First Quarter.
Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other
Rent, clinic supplies, contract labor and other were $14.2 million for the 2014 First Quarter and $12.7 million for the 2013 First Quarter. For New Clinics, rent, clinic supplies, contract labor and other amounted to $2.1 million for the 2014 First Quarter. For Mature Clinics, rent, clinic supplies, contract labor and other decreased by $0.6 million in the 2014 First Quarter compared to the 2013 First Quarter. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 20.4% for the 2014 First Quarter and 20.3% for the 2013 First Quarter.
Clinic Operating Costs—Provision for Doubtful Accounts
The provision for doubtful accounts was $1.0 million for the 2014 First Quarter and $1.1 million for the 2013 First Quarter. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.4% for the 2014 First Quarter and 1.7% for the 2013 First Quarter.
Our allowance for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 4.6% at March 31, 2014, as compared to 4.4% at December 31, 2013. Our days sales outstanding was 42 days at March 31, 2014 and 39 days at December 31, 2013.
Corporate Office Costs
Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $7.1 million for the 2014 First Quarter and $6.4 million for the 2013 First Quarter. The increase was primarily due to increase in the number of employees and amount of incentives. As a percentage of net revenues, corporate office costs were 10.2% for both the 2014 First Quarter and 2013 First Quarter.
Interest Expense
Interest expense increased to $253,000 in the 2014 First Quarter compared to $135,000 in the 2013 First Quarter due to a higher average outstanding balance under our revolving credit agreement during the 2014 period compared to the 2013 period. At March 31, 2014, $45,500,000 was outstanding under our revolving credit agreement.
Provision for Income Taxes
The provision for income taxes was $2.9 million for the 2014 First Quarter and $2.5 million for the 2013 First Quarter. During the 2014 and 2013 First Quarters, we accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 41.0% and 38.4%, respectively.
Non-controlling Interests
Net income attributable to non-controlling interests, inclusive of discontinued operations, was $2.1 million for the 2014 First Quarter and $1.9 million for the 2013 First Quarter. Net income attributable to non-controlling interests, exclusive of discontinued operations, was $2.1 million for the 2014 First Quarter and $2.0 million for the 2013 First Quarter or as a percentage of operating income before corporate office costs was 12.6% for the 2014 First Quarter and 13.3% for the 2013 First Quarter.
LIQUIDITY AND CAPITAL RESOURCES
We believe that our business is generating sufficient cash flow from operations to allow us to meet our short-term and long-term cash requirements, other than those with respect to future acquisitions. At March 31, 2014, we had $16.8 million in cash compared to cash of $12.9 million at December 31, 2013. Although the start-up costs associated with opening new clinics and our planned capital expenditures are significant, we believe that our cash and unused availability under our revolving credit agreement are sufficient to fund the working capital needs of our operating subsidiaries, corporate costs, dividends, purchases of our common stock, accrued clinic closure costs, future clinic development and investments through at least March 2015. The amount outstanding under our revolving credit facility was $45.5 million at March 31, 2014 compared to $40.0 million at December 31, 2013. At March 31, 2014, we had $79.5 million available under our revolving credit facility. Significant acquisitions would likely require financing under our revolving credit facility.
During the three months ended March 31, 2014, $3.7 million was provided by operations and $5.5 million was drawn on our revolving credit agreement. The major uses of cash included: purchases of non-controlling interests ($2.8 million), distributions to non-controlling interest partners ($1.4 million) and purchases of fixed assets ($0.8 million).
Effective December 5, 2013, we entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility with a maturity date of November 30, 2018 (“Credit Agreement”). The Credit Agreement is unsecured and has loan covenants, including requirements that we comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Credit Agreement may be used for working capital, acquisitions, purchases of our common stock, dividend payments to our common shareholders, capital expenditures and other corporate purposes. The pricing grid is based on our consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.5% to 2.5% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Credit Agreement include an unused commitment fee ranging from 0.1% to 0.25% depending on our consolidated leverage ratio and the amount of funds outstanding under the Credit Agreement. On March 31, 2014, $45.5 million was outstanding on the revolving credit facility resulting in $79.5 million of availability, and we were in compliance with all of the covenants thereunder.
Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We also from time to time purchase the non-controlling interests in our Clinic Partnerships. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Any large acquisition would likely require financing.
We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting Medicare Rehab Agency status approval initially may not be submitted for six months or more. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the account receivable has been outstanding for at least 120 days.
We generally enter into various notes payable as a means of financing our acquisitions. Our present outstanding notes payable related to certain of the acquisitions of businesses that occurred in 2013 and 2012. For those acquisitions, we entered into several notes payables aggregating $1.7 million. The notes are payable in equal annual installments of principal over two years plus any accrued and unpaid interest. Interest accrues at various interest rates ranging from 3.25% to 4.0% per annum, subject to adjustment. In addition, we assumed leases with remaining terms of 1 month to 6 years for the operating facilities. At March 31, 2014, the balance on these notes payable was $1.2 million.
In conjunction with the above mentioned acquisitions, in the event that a limited minority partner’s employment ceases at any time after three years from the acquisition date, we have agreed to repurchase that individual’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.
As of March 31, 2014, we have accrued $1.6 million related to credit balances and overpayments due to patients and payors. This amount is expected to be paid in 2014.
From September 2001 through December 31, 2008, our Board of Directors (“Board”) authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). In connection with the March 2009 Authorization, we amended our bank credit agreement to permit share repurchases of up to $15,000,000. We are required to retire shares purchased under the March 2009 Authorization. Effective October 24, 2012, we amended the Credit Agreement to permit us to purchase, commencing on October 24, 2012 and at all times thereafter, up to $15,000,000 of our common stock subject to compliance with covenants.
There is no expiration date for the share repurchase program. As of March 31, 2014, there are currently an additional estimated 341,000 shares that may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the three months ended March 31, 2014.
FACTORS AFFECTING FUTURE RESULTS
The risks related to our business and operations include:
- Changes as a result of healthcare reform legislation, and implementation thereof, may affect our business.
- We depend upon reimbursement by third-party payors including Medicare and Medicaid.
- Uncertain economic conditions and the historically high unemployment rate in the United States may have material adverse impacts on our business and financial condition that we currently cannot predict.
- We depend upon the cultivation and maintenance of relationships with the physicians in our markets.
- We also depend upon our ability to recruit and retain experienced physical and occupational therapists.
- Our revenues may fluctuate seasonally due to weather.
- Our operations are subject to extensive regulation.
- We operate in a highly competitive industry.
- We may incur closure costs and losses.
- Future acquisitions may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities.
- Certain of our internal controls, particularly as they relate to billings and cash collections, are largely decentralized at our clinic locations.
See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013.
Forward-Looking Statements
We make statements in this report that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:
- changes as the result of government enacted national healthcare reform;
- changes in Medicare guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status,
- business and regulatory conditions including federal and state regulations;
- changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
- revenue and earnings expectations;
- general economic conditions;
- availability and cost of qualified physical and occupational therapists;
- personnel productivity;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
- maintaining adequate internal controls;
- availability, terms, and use of capital; and
- weather and other seasonal factors.
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see our periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement is no longer accurate.
Market risk
As filed, 549 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts, futures contracts or the like. Our primary market risk exposure is the changes in interest rates obtainable on our Credit Agreement. The interest on our Credit Agreement is based on a variable rate. At March 31, 2014, $45,500,000 was outstanding under our Credit Agreement. Based on the balance of the Credit Agreement at March 31, 2014, any change in the interest rate of 1% would yield a decrease or increase in annual interest expense of $455,000.
Controls and procedures
As filed, 1,386 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, the Company’s management completed an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded (i) that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and (ii) that our disclosure controls and procedures are effective.
(b) Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-01-01 to 2014-03-31 | $69.8m | us-gaap:SalesRevenueNet |
| Gross profit | 3 months2014-01-01 to 2014-03-31 | $16.6m | us-gaap:GrossProfit |
| Operating income | 3 months2014-01-01 to 2014-03-31 | $9.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2014-01-01 to 2014-03-31 | $253.0k | us-gaap:InterestExpense |
| Income tax | 3 months2014-01-01 to 2014-03-31 | $2.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-01-01 to 2014-03-31 | $4.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-01-01 to 2014-03-31 | $0.27 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-01-01 to 2014-03-31 | $0.27 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-01-01 to 2014-03-31 | 12,144,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2014-01-01 to 2014-03-31 | $3.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2014-01-01 to 2014-03-31 | $849.0k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2014-03-31 | $16.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-03-31 | $54.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-03-31 | $228.6m | us-gaap:Assets |
| Current liabilities | At period end2014-03-31 | $19.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-03-31 | $71.3m | us-gaap:Liabilities |
| Long-term debt | At period end2014-03-31 | $46.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2014-03-31 | $775.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2014-03-31 | $130.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-14-002002. Last ingested by Listed: Nov 14, 2026, 13:45 ET. Listed shows no prices and gives no investment advice.